Literature DB >> 17678830

Monitoring systemic lupus erythematosus in standard clinical care.

Michelle Petri1.   

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a fluctuating and unpredictable course. Monitoring SLE in the routine clinic setting is a challenge because both the disease and its treatment can result in organ damage. Disease activity indices and a cumulative history summary can be used to track complicated patients over time. Monitoring guidelines for damage from the disease and for the toxicity of treatment are available.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678830     DOI: 10.1016/j.berh.2007.01.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  5 in total

1.  Manifestations of systemic lupus erythematosus.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-10

2.  Priority-setting tools for rheumatology disease referrals: a review of the literature.

Authors:  Carolyn De Coster; Avril Fitzgerald; Monica Cepoiu
Journal:  Clin Rheumatol       Date:  2008-06-17       Impact factor: 2.980

Review 3.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Authors:  Michael P Cancro; David P D'Cruz; Munther A Khamashta
Journal:  J Clin Invest       Date:  2009-05-01       Impact factor: 14.808

4.  Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study.

Authors:  Linda L D Zhong; Zhao Xiang Bian; Jun Hua Gu; Xin Zhou; Yu Tian; Jian Chun Mao; Xiang Jun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

5.  High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus.

Authors:  Ali A Al-Jabri; Amal K Al-Gahdani; Ibtisam Al-Shuaili
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 3.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.